Physician profile
Daniel Carter
NPI 1699919944
$3,139.86
in general payments reported to CMS, 2019-2025
33 companies · $713 in 2025
The $713 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $147 · 2021: $135 · 2022: $533 · 2023: $488 · 2024: $627 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $674.89 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $309.49 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, Lp | $214.32 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sobi, INC | $205.90 | 2019-2023 | |
| Pfizer INC. | $179.35 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $174.28 | 2022-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $159.85 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $118.25 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Welch Allyn | $117.60 | 2021 | |
| Baxter Healthcare | $117.60 | 2022 | |
| Tris Pharma INC | $115.26 | 2019-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $92.82 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $91.20 | 2024-2025 | |
| Sanofi Pasteur INC. | $61.85 | 2019-2025 | |
| Hologic Sales and Service, LLC | $49.59 | 2022-2024 | Aptima |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.93 | 2019-2023 | Bexsero |
| Astrazeneca Pharmaceuticals Lp | $45.34 | 2023-2024 | Flumist Quadrivalent |
| Shire North American Group INC | $39.82 | 2019 | |
| Verrica Pharmaceuticals INC. | $34.50 | 2024-2025 | Ycanth |
| Noven Therapeutics, LLC | $31.10 | 2024 | Xelstrym |
| Genentech USA, INC. | $28.13 | 2019-2020 | |
| Adlon Therapeutics L.P. | $27.94 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $23.48 | 2024 | Daybue |
| Neurelis, INC. | $22.08 | 2023 | Valtoco |
| Noven Pharmaceuticals, INC. | $20.36 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $19.25 | 2025 | Relexxii |
| Mission Pharmacal Company | $18.54 | 2019 | |
| Organon LLC | $17.60 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.45 | 2024 | |
| Rhodes Pharmaceuticals L.P. | $17.06 | 2019 | |
| Seqirus USA INC | $16.95 | 2025 | Flucelvax |
| Alk-Abello, INC | $15.66 | 2025 | Neffy, Odactra, Grastek |
| Mylan Pharmaceuticals INC. | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.